An oral Edaravone formulation designed by Parikh and colleagues (Parikh, Kathawala, Tan, et al. 2018; Parikh, Kathawala, Li, et al. 2018) using Soluplus as a carrier and a self‐nano micellizing solid dispersion strategy was able to dose‐dependently reverse the cognitive deficits and mood disorders of very old APP/PS1 mice (17 months). Here, APP is linked to Cognitive impairment.